The global vibrio diagnostics market has increased healthcare expenditure, rising awareness, advancement in the diagnostics techniques such as enzyme immunoassays (EIA), and polymerase chain reaction (PCR), along with the affordability of diagnostics devices and kits and rapid diagnostics tests as its major drivers in the coming years. Growing peri-urban slums, uncooked and raw seafood intake, the inadequacy of clean water, and improper sanitation, unhygienic living conditions are the important factors for the growth of cholera and other diseases during the forecast period. Favorable living environment for the bacteria due to global warming is considered to be the other important factor leading to the growth of diseases thereby leading to the growth of the market. Vibrio bacteria are mostly found in the estuarine and marine environments. To some extent, they are also available in the freshwater environment and are usually found in subtropic and temperate waters. Various species of vibrio causes seafood borne illness such as wound infections and septicaemia. There are almost a dozen species that can cause diseases in humans and accounted for 100 deaths, 500 hospitalizations, and 80,000 illnesses in the U.S. every year. Vibrio diagnostics market is segmented into technology and end users. Technology has been further classified into PCR, monoclonal antibodies, flow cytometry, enzyme immunoassays (EIA), diagnostic imaging, immunoprecipitation, Fluorescent immunoassays, and immune-PCR.
End-users of vibrio diagnostics market include hospitals, Public Health Laboratories, Private diagnostic labs, and commercial diagnostic labs. Geographically, the Vibrio diagnostics market is studied with respect to four regions as North America, Europe, RoW, and Asia Pacific. Recently, new variant strains have been identified in some parts of Africa and Asia and according to the observations they are expected to cause severe cholera with increasing cases of fatality rates. Inadequate environmental management in the growing economies of the Asia Pacific such as India and China owing to the rising population and pollution is expected to drive the market during the forecast period. According to the CDC, there is an average of 16 deaths, 45 hospitalizations, and 50 confirmed cases along the Gulf Coast each year. Some of the key players in this market are Dickinson and Company, Lonza Group, Abbott Laboratories, DiamedixImpex S.A., Novartis Diagnostics, Kreatech Holding BV, F. Hoffmann-La Roche Ltd, Fujirebio Diagnostics Inc., Becton, and Eiken Chemical Co. Ltd.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.